Literature DB >> 35490919

Precision intervention for prostate cancer: Re-evaluating who is at risk.

Alexandros Papachristodoulou1, Cory Abate-Shen2.   

Abstract

The vast majority of new prostate cancer diagnoses are low-grade tumors that are monitored by active surveillance rather than undergoing immediate treatment. However, a subset of men will progress to advanced prostate cancer which may result in lethality, and these men are likely to benefit from early intervention to prevent or delay such progression. For this high-risk group, which includes aged men, men of African descent, and those with a hereditary predisposition to prostate cancer, informed risk stratification can be the cornerstone of clinical decision making and treatment intervention. In this review, we discuss the importance of a precision intervention approach that considers the cumulative risk for a given patient or population to develop prostate cancer or to progress to lethal disease, with particular focus on the interplay of major determinants of high-risk disease.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active surveillance; Genetic variants; Mitochondrial DNA; Precision prevention and treatment; Risk factors

Mesh:

Substances:

Year:  2022        PMID: 35490919      PMCID: PMC9136709          DOI: 10.1016/j.canlet.2022.215709

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   9.756


  169 in total

Review 1.  Bringing Prostate Cancer Germline Genetics into Clinical Practice.

Authors:  Sanjay Das; Simpa S Salami; Daniel E Spratt; Samuel D Kaffenberger; Michelle F Jacobs; Todd M Morgan
Journal:  J Urol       Date:  2019-07-08       Impact factor: 7.450

2.  The impact of racial residential segregation on prostate cancer diagnosis and treatment.

Authors:  Michael R Poulson; Samuel A Helrich; Kelly M Kenzik; Tracey A Dechert; Teviah E Sachs; Mark H Katz
Journal:  BJU Int       Date:  2020-12-01       Impact factor: 5.588

3.  Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.

Authors:  Rong Na; S Lilly Zheng; Misop Han; Hongjie Yu; Deke Jiang; Sameep Shah; Charles M Ewing; Liti Zhang; Kristian Novakovic; Jacqueline Petkewicz; Kamalakar Gulukota; Donald L Helseth; Margo Quinn; Elizabeth Humphries; Kathleen E Wiley; Sarah D Isaacs; Yishuo Wu; Xu Liu; Ning Zhang; Chi-Hsiung Wang; Janardan Khandekar; Peter J Hulick; Daniel H Shevrin; Kathleen A Cooney; Zhoujun Shen; Alan W Partin; H Ballentine Carter; Michael A Carducci; Mario A Eisenberger; Sam R Denmeade; Michael McGuire; Patrick C Walsh; Brian T Helfand; Charles B Brendler; Qiang Ding; Jianfeng Xu; William B Isaacs
Journal:  Eur Urol       Date:  2016-12-15       Impact factor: 20.096

4.  Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.

Authors:  Anis A Hamid; Kathryn P Gray; Grace Shaw; Laura E MacConaill; Carolyn Evan; Brandon Bernard; Massimo Loda; Niall M Corcoran; Eliezer M Van Allen; Atish D Choudhury; Christopher J Sweeney
Journal:  Eur Urol       Date:  2018-12-12       Impact factor: 20.096

Review 5.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

Review 6.  Redox Regulation in Cancer Cells during Metastasis.

Authors:  Alpaslan Tasdogan; Jessalyn M Ubellacker; Sean J Morrison
Journal:  Cancer Discov       Date:  2021-10-14       Impact factor: 39.397

7.  African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.

Authors:  Roshan A Karunamuni; Minh-Phuong Huynh-Le; Chun C Fan; Wesley Thompson; Rosalind A Eeles; Zsofia Kote-Jarai; Kenneth Muir; Artitaya Lophatananon; Catherine M Tangen; Phyllis J Goodman; Ian M Thompson; William J Blot; Wei Zheng; Adam S Kibel; Bettina F Drake; Olivier Cussenot; Géraldine Cancel-Tassin; Florence Menegaux; Thérèse Truong; Jong Y Park; Hui-Yi Lin; Jeannette T Bensen; Elizabeth T H Fontham; James L Mohler; Jack A Taylor; Luc Multigner; Pascal Blanchet; Laurent Brureau; Marc Romana; Robin J Leach; Esther M John; Jay Fowke; William S Bush; Melinda Aldrich; Dana C Crawford; Shiv Srivastava; Jennifer C Cullen; Gyorgy Petrovics; Marie-Élise Parent; Jennifer J Hu; Maureen Sanderson; Ian G Mills; Ole A Andreassen; Anders M Dale; Tyler M Seibert
Journal:  Int J Cancer       Date:  2020-09-24       Impact factor: 7.396

8.  Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.

Authors:  Xian Liu; Tristan R Grogan; Haley Hieronymus; Takao Hashimoto; Jack Mottahedeh; Donghui Cheng; Lijun Zhang; Kevin Huang; Tanya Stoyanova; Jung Wook Park; Ruzanna O Shkhyan; Behdokht Nowroozizadeh; Matthew B Rettig; Charles L Sawyers; David Elashoff; Steve Horvath; Jiaoti Huang; Owen N Witte; Andrew S Goldstein
Journal:  Cell Rep       Date:  2016-12-06       Impact factor: 9.423

9.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

Authors:  Elena Castro; Chee Goh; David Olmos; Ed Saunders; Daniel Leongamornlert; Malgorzata Tymrakiewicz; Nadiya Mahmud; Tokhir Dadaev; Koveela Govindasami; Michelle Guy; Emma Sawyer; Rosemary Wilkinson; Audrey Ardern-Jones; Steve Ellis; Debra Frost; Susan Peock; D Gareth Evans; Marc Tischkowitz; Trevor Cole; Rosemarie Davidson; Diana Eccles; Carole Brewer; Fiona Douglas; Mary E Porteous; Alan Donaldson; Huw Dorkins; Louise Izatt; Jackie Cook; Shirley Hodgson; M John Kennedy; Lucy E Side; Jacqueline Eason; Alex Murray; Antonis C Antoniou; Douglas F Easton; Zsofia Kote-Jarai; Rosalind Eeles
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

10.  Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.

Authors:  Cathleen Nientiedt; Jan Budczies; Volker Endris; Martina Kirchner; Constantin Schwab; Christina Jurcic; Rouven Behnisch; Shirin Hoveida; Philippa Lantwin; Adam Kaczorowski; Christine Geisler; Svenja Dieffenbacher; Fabian Falkenbach; Desiree Franke; Magdalena Görtz; Martina Heller; Ruth Himmelsbach; Carine Pecqueux; Mathias Rath; Philipp Reimold; Viktoria Schütz; Iva Simunovic; Elena Walter; Luisa Hofer; Claudia Gasch; Gita Schönberg; Lars Pursche; Gencay Hatiboglu; Joanne Nyarangi-Dix; Holger Sültmann; Stefanie Zschäbitz; Stefan A Koerber; Dirk Jäger; Jürgen Debus; Anette Duensing; Peter Schirmacher; Markus Hohenfellner; Albrecht Stenzinger; Stefan Duensing
Journal:  Urol Oncol       Date:  2021-07-26       Impact factor: 3.498

View more
  1 in total

1.  Urinary symptoms and prostate cancer-the misconception that may be preventing earlier presentation and better survival outcomes.

Authors:  Vincent J Gnanapragasam; David Greenberg; Neil Burnet
Journal:  BMC Med       Date:  2022-08-04       Impact factor: 11.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.